# Sunil Shah

> Sunil Shah is a seed investor at Alevin Therapeutics backing Health Care and Biotechnology. See 11 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Alevin Therapeutics](https://shizune.co/investors/profile/alevin-therapeutics)
- Location: Cambridge, United States
- Total investments: 11
- Last investment: Apr 2021
- Lead investor: 82%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/sunil-shah-4bb225
- X (Twitter): https://twitter.com/sunilshah123
- Facebook: https://www.facebook.com/sunil.shah.963434

Sunil Shah is a seed investor at Alevin Therapeutics in Cambridge focused on Health Care and Biotechnology. Sunil Shah is the CEO and Co-Founder of o2h group. He previously worked at India-UK Cancer Research Initiative (CRUK-DBT) as an Advisory Panel Member. Sunil Shah attended the University of Cambridge.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 9 | 82% |
| Biotechnology | 7 | 64% |
| Biopharma | 5 | 45% |
| Pharmaceutical | 4 | 36% |
| Health Diagnostics | 3 | 27% |

16 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 6 | 55% |
| Series A | 2 | 18% |
| Pre-Seed | 1 | 9% |
| Funding Round | 1 | 9% |
| Post-IPO Equity | 1 | 9% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Stingray Bio | Stingray Bio is ab biotechnology company that targets LMTK3 kinase to develop precision therapeutics for treating cancer. |  | Seed | Apr 08, 2021 |  |
| Spirea | Spirea Ltd. operates as a healthcare technology company that has developed a smart polymer platform for the controlled delivery of drug combinations to maximise the clinical impact of medicines. |  | Seed | Jan 22, 2021 |  |
| Tay Therapeutics | Tay Therapeutics is a drug discovery company that develops the next generation of topical and oral therapies for inflammatory conditions. |  | Pre-Seed | Nov 27, 2020 |  |
| Cortirio | Cortirio is a portable diagnosis of brain injuries. Traumatic brain injury is the leading cause of death and disability among the under 40s. Our portable scanners can be used at the point of care to rapidly diagnose and monitor traumatic brain injuries. Saving time saves brain function, preventing disability and death. |  | Seed | Oct 15, 2020 |  |
| Neurofenix | Aiming to make rehabilitation more autonomous, enjoyable and accessible to stroke victims. |  | Seed | Feb 15, 2020 |  |
| Small Pharma | Small Pharma applies expert intellectual property design to guide academic discovery to commercial product. We operate a scalable model of outsourced drug development. We assemble specific expert teams to design and execute development programs with demonstrated track-records in all disciplines essential to their success. |  |  | Jul 18, 2019 |  |
| Metrion Biosciences | Metrion Biosciences is a Contract Research Organization (CRO) that is located in the world renowned Cambridge biocluster. |  | Series A | Apr 01, 2019 |  |
| DeepMatter Group | Deepmatter Group Plc is a big data and analysis company which has built a platform - DigitalGlassware™, focused on enabling reproducibility in chemistry. It continues to develop this software to deliver applications resulting in new optimised chemicals, materials and formulations in such commercially significant areas as pharmaceutical research,fine chemicals, scientific publications and teaching. Deepmatter is at the forefront of the digitization of chemistry, which will ultimately see the enabling of an autonomous synthesis engine, the Chemputer™. |  | Post-IPO Equity | Mar 18, 2019 |  |
| Exonate | Exonate is a privately held, early stage, biotech company spun out of the University of Nottingham that is focused on alternative splicing of Vascular Endothelial Growth Factor (VEGF) in ophthalmology. Exonate’s lead programme is focused on Diabetic Macular Oedema (DMO). A consequence of diabetic retinopathy, DMO, is swelling in an area of theretina called the macula and wet Age-Related Macular Degeneration (wAMD), which is the leading cause of vision loss in people aged 60 and older. The Company is founded on scientific excellence with strong links to Professor David Bates and his lab at Nottingham University specializing in the biology and biochemical pathways of VEGF splice variants.Exonate have developed small molecules that inhibit production of pro-angiogenic VEGF through selective inhibition of serine/threonine-protein kinase 1 (SRPK1)-mediated VEGF splicing. These inhibitors have already demonstrated superior efficacy as topical agents in preclinical models of wet AMD. Through a Wellcome Trust funded project, Exonate has completed an optimization programme and has nominated a pre-clinical candidate drug with optimal characteristics.During the second quarter of 2020 regulatory toxicology and safety pharmacology studies have taken place. This is to support the successful application to the regulatory authorities for clinical evaluation. Exonate is led by an experienced, international management team that has previously worked together with cross-disciplinary experience in medicine and drug development, as well as successful fundraising for early stage companies.About Diabetic Macular Oedema (DMO)*: DMO is the build-up of fluid (Oedema) in a region of the retina called the macula. The macula is important for the sharp, straight-ahead vision that is used for reading, recognizing faces, and driving. DMO is the most common cause of vision loss among people with diabetic retinopathy. About half of all people with diabetic retinopathy will develop DMO and although it is more likely to occur as diabetic retinopathy worsens, DMO can happen at any stage of the disease.About wet Age-Related Macular Degeneration (wet AMD): Today, wet AMD is a leading cause of vision loss in people aged 60 years or older and affects more than 30 million patients worldwide, over 200,000 of those in the UK alone. If untreated patients are likely to lose sight in the affected eye within 24 months of disease onset.The main currently available treatment options for DMO and wet AMD are: • anti-VEGF antibody drugs – to prevent the growth of new blood vessels in the eye. Unlike small molecule drugs or eye drops these treatments must be injected into the eye once every 1 or 2 months. Resistance can develop to these drugs causing the disease to progress anew. • Laser surgery – to destroy abnormal blood vessels in the eye. This type of surgery is only suitable if blood vessel damage is not too extensive and if the abnormal blood vessels aren't close to the fovea, as performing surgery close to this part of the eye can cause permanent vision loss. • With DMO, Corticosteroids either injected or implanted into the eye, may be used alone or in combination with other drugs or laser surgery to treat DMO.*source: https://nei.nih.gov/health/diabetic/retinopathy | $1.9M | Series A | Jan 03, 2019 |  |
| Stemnovate | Stemnovate is a unique, innovative drug development platforms enable the right patients to be targeted with the right treatments, at the right time. |  | Seed | May 25, 2018 |  |

10 of 11 investments shown.

## Co-investors
- [Amadeus Capital Partners](https://shizune.co/investors/profile/amadeus-capital-partners) — VC Fund, 1 deal together
- [Cambridge Angels group](https://shizune.co/investors/profile/cambridge-angels-group) — VC Fund, 1 deal together
- [Meltwind Advisory](https://shizune.co/investors/profile/meltwind-advisory) — VC Fund, 1 deal together
- [Social Tech Trust](https://shizune.co/investors/profile/nominet-trust) — VC Fund, 1 deal together
- [Parkwalk Advisors](https://shizune.co/investors/profile/parkwalk-advisors) — VC Fund, 1 deal together
- [SyndicateRoom](https://shizune.co/investors/profile/syndicateroom) — VC Fund, 1 deal together

## About Alevin Therapeutics

VC Fund · Cambridge, United Kingdom

Alevin Therapeutics is creating breakthrough approaches to safe and effective medicines for patients with life-threatening diseases.

2 contacts available at Alevin Therapeutics.

| Name | Title | Profile |
| --- | --- | --- |
| Sunil Shah | Executive Chairman | https://shizune.co/investors/profile/sunil-shah-0e17 |
| Sunil Shah | Executive Chairman | https://shizune.co/investors/profile/sunil-shah-2 |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Sunil Shah invest in?

Sunil Shah invests primarily in Health Care, Biotechnology and Biopharma startups, most often at Seed and Series A stage. Most of the 11 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Sunil Shah last invest?

The most recent investment recorded for Sunil Shah closed in Apr 2021. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co